Alprostadil (Caverject/MUSE) Side-Effect Reports from Real Users

What Clinical Trials Found About Alprostadil Side Effects

Penile pain remains the single most reported adverse event across every major alprostadil trial. In the landmark Linet and Ogrinc study (NEJM, 1996; N=296), 50% of intracavernosal injection users reported penile pain at some point during the study period, though only 11% rated it as moderate or severe. The pain typically began within minutes of injection and resolved within 60 minutes.

Prolonged erection (defined as lasting 4-6 hours) occurred in approximately 4% of patients in key Caverject trials, while true priapism (erection exceeding 6 hours requiring intervention) appeared in roughly 1% of users. Penile fibrosis, including palpable nodules and Peyronie's-like curvature, developed in approximately 7.8% of patients using intracavernosal alprostadil over 18 months of follow-up. Hematoma at the injection site occurred in 3-5% of patients, according to FDA prescribing information for Caverject.

For MUSE (intraurethral delivery), the side-effect profile shifts. A multicenter study by Padma-Nathan et al. (NEJM, 1997; N=1,511) found urethral pain or burning in 32.7% of patients and minor urethral bleeding in 4.8%. Dizziness occurred in 1.9%, and symptomatic hypotension in 3.3%. No cases of penile fibrosis were reported with MUSE in that trial, a meaningful difference from the injection formulation.

How Real Users Describe Injection Pain

The clinical statistic of "50% report pain" does not capture the texture of the experience. Across Reddit threads in r/erectiledysfunction and r/Trt, the most common description is a "deep ache" or "burning" that begins 2-3 minutes after injection and peaks around the 5-minute mark. Several users compare it to a dull toothache localized in the shaft.

A consistent pattern in Drugs.com user reviews and online forums is dose dependence. Users who titrated from 10 mcg to 20 mcg or higher frequently report a noticeable increase in discomfort. One Drugs.com reviewer noted: "At 10 mcg, barely felt it. At 20, there was a definite ache for 15-20 minutes. At 40, I almost stopped using it." This aligns with the dose-response pain data from Porst (1996), which documented a near-linear relationship between alprostadil dose and pain severity scores.

Some users describe adaptation over time. A subset of reviewers on multiple platforms report that pain intensity decreased after 4-6 uses, consistent with findings from a 12-month open-label extension study where the proportion of patients rating pain as moderate or severe dropped from 11% at month one to 4% by month twelve. Whether this reflects physiological habituation or improved injection technique is unclear from both the published data and user accounts.

MUSE-Specific Complaints: Burning, Bleeding, and Dizziness

The intraurethral pellet (MUSE) trades injection anxiety for a different set of complaints. Urethral burning is the dominant user-reported issue, described on forums as ranging from "mild warmth" to "feels like a UTI for 10 minutes." The Padma-Nathan et al. trial documented urethral pain in 32.7% of patients, but real-world reports suggest the subjective intensity varies widely with pellet placement technique.

Minor urethral bleeding (spotting on underwear or at the meatus) appears in user reports at a rate broadly consistent with the 4.8% trial figure. Most users describing this side effect call it cosmetically alarming but painless. A smaller group reports recurrent spotting that led them to discontinue.

Dizziness and near-syncope get disproportionate attention in user forums relative to their actual incidence. The FDA-approved MUSE prescribing information lists hypotension in 3.3% and syncope in 0.4% of clinical trial participants. On Reddit, dizziness posts tend to come from first-time users who did not follow the recommended 10-minute standing/walking period after administration, a protocol detail that the American Urological Association guidelines specifically emphasize.

Female partner vaginal burning is another MUSE-specific complaint that surfaces in forums. The Padma-Nathan data reported mild vaginal irritation in 5.8% of partners. Users consistently recommend condom use if a partner reports discomfort, a practice also noted in the prescribing label.

Priapism: The Side Effect Users Fear Most

Priapism generates more anxiety than any other alprostadil side effect, despite being relatively uncommon. The Linet and Ogrinc key trial reported prolonged erection (4-6 hours) in 4% and true priapism (>6 hours) in approximately 1% of patients. A post-marketing surveillance analysis covering over 4,700 patients found a priapism rate of 1.3% over a mean follow-up of 2.4 years.

Reddit accounts of priapism tend to be vivid and cautionary. Users who experienced prolonged erections consistently describe the decision point: "Do I wait it out or go to the ER?" The AUA guideline on priapism management recommends emergency aspiration and phenylephrine injection for any erection lasting beyond 4 hours, and multiple forum users describe this procedure in graphic detail.

A pattern in user reports is that priapism events cluster around dose titration. Users switching from a lower dose to a higher one, or using alprostadil after a period of abstinence without re-titrating, account for a disproportionate share of priapism reports. The Caverject prescribing information explicitly warns against self-dose-escalation, but user accounts suggest that compliance with this guidance is inconsistent in practice.

Penile Fibrosis and Long-Term Structural Concerns

Fibrosis is the side effect with the most significant long-term implications. Palpable nodules, plaque formation, and penile curvature have been documented in 3-8% of long-term intracavernosal injection users across studies. A systematic review by Chew and Stuckey (2005) found that fibrosis rates increased with injection frequency and duration of use, with patients injecting more than twice weekly showing notably higher risk.

User forum discussions about fibrosis carry a different tone than discussions of pain or priapism. Pain is temporary. Fibrosis represents a potentially permanent structural change. Several long-term users on r/erectiledysfunction describe discovering a "hard bump" or noticing curvature developing after 1-2 years of regular injection use. The Linet and Ogrinc data showed fibrosis in 7.5% of their cohort, with most cases detected on palpation rather than by patient self-report.

Injection technique appears to matter significantly. Users who report rotating injection sites and using the recommended lateral approach to the corpus cavernosum describe lower rates of nodule formation in their anecdotal accounts. The clinical literature supports this: a prospective study by Lakin et al. found that strict site rotation and proper needle gauge selection reduced fibrosis incidence.

How Side Effects Compare to PDE5 Inhibitors

Users who arrive at alprostadil have typically failed oral PDE5 inhibitors like sildenafil (Viagra) or tadalafil (Cialis). Their comparative reports provide useful context. The side-effect profile of sildenafil centers on headache (16%), flushing (10%), dyspepsia (7%), and visual disturbances (3%). These are systemic. Alprostadil's side effects are predominantly local.

Multiple users note this trade-off explicitly. A common sentiment on forums is: "I'd rather have 15 minutes of penile aching than 6 hours of headache and sinus pressure." Others disagree, finding the injection process itself to be a psychological barrier that no amount of efficacy can overcome.

The Eardley et al. (2010) meta-analysis found that patient satisfaction with intracavernosal alprostadil remained high at 87% despite the pain reports, largely because the patients using it had already failed less invasive options. Selection bias clearly operates here: these are motivated users who accept a higher side-effect burden in exchange for reliable erections. A subsequent satisfaction study found that 72% of intracavernosal injection users continued therapy at 2 years, suggesting that most patients considered the side effects manageable relative to the benefit.

Psychological and Relational Side Effects

Clinical trials rarely capture the psychological dimension, but user forums discuss it extensively. Injection anxiety is a recurring theme. Multiple users describe a "flinch reflex" that took weeks to overcome, and several report that performance improved once a partner administered the injection rather than the patient himself.

The prescribed spontaneity window also generates frustration. The 5-15 minute onset time requires planning that oral medications do not. Users who previously took tadalafil (with its 36-hour activity window) describe the transition as "going from a daily vitamin to a medical procedure." This framing, where the treatment itself feels clinical, is cited by multiple discontinuers as their primary reason for stopping.

Partner reactions are mixed in user accounts. Some partners express discomfort with the injection process or concern about the medication's safety. Others describe relief that an effective treatment exists after months or years of untreated ED. The Althof et al. (2001) partner satisfaction data found that 62% of partners rated overall satisfaction as good or excellent during intracavernosal therapy, a figure that tracks reasonably well with the more positive forum accounts.

Sample Size Caveats and Selection Bias in User Reports

Every user-review dataset carries significant limitations. Drugs.com reviews for alprostadil products number in the low hundreds, not thousands, and the population who posts online reviews skews toward extreme experiences (very positive or very negative). The Linet and Ogrinc study enrolled 296 patients in a controlled environment with standardized dosing. Real-world users self-titrate, skip office visits, and vary their injection technique.

Reddit communities like r/erectiledysfunction and r/Trt have active membership but small alprostadil-specific subpopulations. A thread with 15-20 comments represents a tiny fraction of the estimated 300,000+ annual US prescriptions for alprostadil products. Negative experiences are overrepresented in these venues because users seeking help with side effects are more likely to post than users whose therapy is working uneventfully.

The clinician's perspective offers necessary balance. Dr. Irwin Goldstein, a urologist who contributed to early alprostadil research, has noted that "the majority of patients who learn proper injection technique tolerate intracavernosal alprostadil well, and the dropout rate is driven more by the psychology of self-injection than by pharmacologic side effects." This observation aligns with the long-term continuation data showing that technique-related barriers outpace side-effect-related discontinuation.

Treat online reviews as qualitative signal, not quantitative evidence. They are most useful for identifying side effects that clinical trials may undercount (psychological burden, partner effects, injection-site technique issues) and least useful for estimating how common any given side effect actually is.